Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $37.0800 (5.55%) ($37.0800 - $37.1100) on Mon. Jun. 7, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.48% (three month average) | RSI | 65 | Latest Price | $37.0800(5.55%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 1.3% a day on average for past five trading days. | Weekly Trend | TGTX advances 2.8% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(68%) ARKG(63%) ARKK(59%) IBB(59%) IWO(59%) | Factors Impacting TGTX price | TGTX will decline at least -1.74% in a week (0% probabilities). VIXM(-45%) VXX(-38%) UUP(-19%) UNG(-3%) TLT(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.74% (StdDev 3.48%) | Hourly BBV | 2.2 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $35.09(5.67%) | 10 Day Moving Average | $34.6(7.17%) | 20 Day Moving Average | $34.63(7.07%) | To recent high | -26.4% | To recent low | 14.3% | Market Cap | $4.696b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |